Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

FDA published a final version of its guidance document, “Communications From Firms to Health Care Providers Regarding ...

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial. Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025. SEATTLE and VANCOUVER, British C ...

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...

Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...